Previous 10 | Next 10 |
home / stock / tlt:cc / tlt:cc news
--News Direct-- Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share interim data from a Phase II clinical study designed to treat patients diagnosed with Bacillus Calmette-Guérin Unresponsive, Non-Muscle Invasive Bladder Cancer and Carcinoma I...
TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds (" PDCs ") and their associ...
In the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this press release. TORONTO, ON / ACCESSWIRE / May 30, 2023 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLT...
TORONTO, ON / ACCESSWIRE / May 30 2023 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDCs ") and their associate...
TORONTO, ON / ACCESSWIRE / May 24, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds (" PDCs ") and their assoc...
For the primary objective, 65% of Evaluable Patients (Patients evaluated by a Principal Investigator ("PI")) achieved a Complete Response ("CR") at any assessment date post primary Study Treatment and 30% of Evaluable Patients achieved a CR at 450 days. TORONTO, ON / ACCESSWIRE / May 10, 2023...
TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo D...
TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase ® Technologies Inc. (“ Theralase ® ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light acti...
TORONTO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Theralase ® Technologies Inc. (“ Theralase ® ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light ...
TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“ Theralase® ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Phot...
News, Short Squeeze, Breakout and More Instantly...
Theralase Technologies Inc. Company Name:
TLT:CC Stock Symbol:
TSXVC Market:
Theralase Technologies Inc. Website:
TORONTO, ON / ACCESSWIRE / July 8, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ...
TORONTO, ON / ACCESSWIRE / June 20, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formu...
TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formu...